Prognostic impact of adding bevacizumab to carboplatin and paclitaxel for recurrent, persistent, or metastatic cervical cancer

• Published in: Taiwanese journal of obstetrics & gynecology Vol. 61; no. 5; pp. 818 - 822
• Main Authors: Yasunaga, Masafumi, Yahata, Hideaki, Okugawa, Kaoru, Shimokawa, Mototsugu, Maeda, Yumiko, Hori, Emiko, Kodama, Keisuke, Yagi, Hiroshi, Ohgami, Tatsuhiro, Onoyama, Ichiro, Asanoma, Kazuo, Kato, Kiyoko
• Format: Journal Article
• Language: English
• Published: Elsevier 01.09.2022
• Subjects: Bevacizumab; Carboplatin; Drug therapy; Prognosis; Uterine cervical neoplasms
• ISSN: 1028-4559
• DOI: 10.1016/j.tjog.2022.06.005

Objective: Recent randomized phase III trial has shown significant benefit in overall survival (OS) for patients with advanced cervical cancer by adding bevacizumab to conventional chemotherapy. The aim of this study was to evaluate the prognostic impact for Japanese recurrent, persistent, or metastatic cervical cancer patients where bevacizumab was added to paclitaxel plus carboplatin. Materials and methods: A retrospective analysis was performed on 90 patients with recurrent, persistent, or metastatic cervical cancer mainly treated by paclitaxel plus carboplatin between 2005 and 2019 at our hospital. Data for the following clinicopathological variables were analyzed: (1) bevacizumab use; (2) histology; (3) disease presentation; (4) performance status; (5) prior chemotherapy containing platinum agent; (6) pelvic disease; (7) prior pelvic radiotherapy; (8) location of target lesions. Survival analysis was performed using Kaplan–Meier curves, log-rank tests, Wilcoxon tests, and Cox proportional hazards models combined with propensity score matching. Results: Adding bevacizumab to paclitaxel plus carboplatin showed significantly increased complete response to compared with that of non-users. In a Cox regression hazard model, bevacizumab use tended to show better OS though without statistically significance. After propensity score matching, adding bevacizumab to paclitaxel plus carboplatin showed a significant better OS by univariate analysis using Wilcoxon test, not by log-rank test. Conclusion: Adding bevacizumab to paclitaxel plus carboplatin showed a limited prognostic impact for recurrent, persistent or advanced cervical cancer patients in the real world. Further effective second-line treatments are needed to prolong OS of patients with recurrent, persistent or advanced cervical cancer.